|
Originally published In Press as doi:10.1074/jbc.M005231200 on July 24, 2000
J. Biol. Chem., Vol. 275, Issue 40, 31460-31468, October 6, 2000
CD43-mediated Signals Induce DNA Binding Activity of AP-1,
NF-AT, and NF B Transcription Factors in Human T Lymphocytes*
M. Angélica
Santana ,
Gustavo
Pedraza-Alva ,
Norma
Olivares-Zavaleta ,
Vicente
Madrid-Marina§,
Vaclav
Horejsi¶,
Steven J.
Burakoff , and
Yvonne
Rosenstein **
From the Instituto de
Biotecnología/Universidad Nacional Autónoma de
México, Apartado Postal 510-3 Cuernavaca, Morelos 62250, México, the § Departamento de Inmunología
Viral, Centro de Investigaciones sobre Enfermedades Infecciosas,
Instituto Nacional de Salud Pública, Cuernavaca, Morelos 62508, México, the ¶ Institute of Molecular Genetics, Academy of
Sciences of the Czech Republic, 14220 Prague, Czech Republic, and the
Dana Farber Cancer Institute and Department of Pediatrics,
Harvard Medical School, Boston, Massachusetts 02115
Received for publication, June 16, 2000
 |
ABSTRACT |
Although numerous reports document a role for
CD43 in T cell signaling, the direct participation of this molecule in
cell activation has been questioned. In this study we show that CD43 ligation on human normal peripheral T cells was sufficient to induce
interleukin-2, CD69, and CD40-L gene expression, without requiring signals provided by additional receptor molecules. This response was partially inhibited by cyclosporin A and staurosporine, suggesting the participation of both the Ca2+ and the
protein kinase C pathways in CD43 signaling. Consistent with the
transient CD43-dependent intracellular Ca2+
peaks reported by others, signals generated through the CD43 molecule
resulted in the induction of NF-AT DNA binding activity. CD43-dependent signals resulted also in AP-1 and NF B
activation, probably as a result of protein kinase C involvement. AP-1
complexes bound to the AP-1 sequence contained c-Jun, and those bound
to the NF-AT-AP-1 composite site contained c-Jun and Fos. NF B
complexes containing p65 could be found as early as 1 h after CD43
cross-linking, suggesting that CD43 participates in early events of T
cell activation. The induction of the interleukin-2, CD69, and CD-40L
genes and the participation of AP-1, NF-AT, and NF B in the
CD43-mediated signaling cascade implicate an important role for this
molecule in the regulation of gene expression and cell function.
 |
INTRODUCTION |
Successful activation of T lymphocytes requires at least two kinds
of signals: those generated by the specific interaction of the
TcR1 with
peptides presented by major histocompatibility complex molecules on the antigen presenting cells and those resulting from the
interaction of other T cell surface molecules, known as co-receptors,
with their ligands on antigen presenting cells (for reviews see
Refs. 1 and 2). Thus, a cell senses not only the presence of an antigen
but also its environment, and a particular cellular response will
result from the integration of signals delivered through the
antigen-specific receptor and the numerous co-receptors.
The CD43 co-receptor is very abundant on T cells surface; it comprises
a highly glycosylated extracellular portion of 239 amino acids that
protrudes 45 nm from the cellular membrane, a transmembrane region, and
a cytoplasmic domain of 123 amino acids (3-5). On T cells, CD43 is
differentially glycosylated in two major isoforms: a 113-123-kDa
product, mainly present on resting CD4+ T cells and a
125-135-kDa form expressed mostly on resting CD8+
lymphocytes, which is up-regulated both on CD4+ and
CD8+ cells, following cellular activation (6). The
125-135-kDa form has been shown to be down-regulated during positive
selection of double positive cells in the thymus, involving CD43 in
thymic selection events (7). Carbohydrate moieties have an important role in CD43 function, because alterations in the glycosylation patterns of the molecule are associated with severe immunodeficiency such as in the case of patients affected with the Wiskott Aldrich syndrome or infected with HIV (8-10). Although there is no direct evidence of how the interaction of CD43 with each of its three reported
ligands intercellular adhesion molecule 1 (CD54), (galectin 1, or major histocompatibility complex I; Refs. 10-12) regulates T cell
function, there is abundant experimental evidence to support the idea
that CD43 participates in T cell adhesion and activation.
Because of its high content of sialic acid residues, resulting in a
strong negative charge, it has been proposed that CD43 functions as an
antiadhesive molecule, providing the cells with a repulsive barrier
(13-15). However, CD43 ligation with specific mAbs has been shown to
promote the formation of homotypic aggregates, some of which were only
partially inhibited with mAbs against lymphocyte integrins, suggesting
an active involvement of CD43 in regulating cellular adhesion (16, 17).
A participation of CD43 in leukocyte rolling was suggested by
experiments where an anti-CD43 mAb inhibited the interaction between T
cells and endothelial cells (18). Evidence that CD43 participates in
TcR-mediated T cell activation has been provided in different
experimental models (for reviews see Refs. 19 and 20). Transfection of a cDNA encoding for human CD43 in a murine T cell hybridoma
specific for human major histocompatibility complex II molecules
resulted in enhanced IL-2 production upon stimulation with the
appropriate antigen presenting cell only if cells expressed the wild
type form of CD43, together with the specific major histocompatibility complex II molecules (21). Co-ligating CD43 with the TcR enhanced T
cell proliferation as compared with cross-linking the TcR alone, in
normal mice2 as
well as in CD28 / mice (22).
To date, the molecular mechanisms that transduce
CD43-dependent signals from the cell surface to the nucleus
are not fully understood. CD43-mediated activation promotes the
generation of second messengers like diacylglycerol and inositol
phosphates, Ca2+ mobilization, and protein kinase C
activation (23). CD43 ligation was shown to induce the association of
Fyn and Lck tyrosine kinases to the cytoplasmic domain of CD43 (24, 25)
and to lead to the formation of a macromolecular complex which
comprises Shc, Grb-2, SLP-76, and the guanine exchange factor Vav (26).
Moreover, CD43-specific signals have been found to promote the nuclear
translocation of ERK2, suggesting that the MAPKs pathway is involved in
the CD43-dependent gene expression (26).
In this study, we provide evidence that CD43-mediated signals are
sufficient to regulate gene expression. We show that CD43 ligation on
human T cells induced IL-2 gene expression without requiring additional
signals provided by other receptor molecules, in opposition to what was
previously reported (27). CD43 signals leading to IL-2 mRNA
synthesis were partially inhibited by the calcineurin inhibitor
cyclosporin A and by the PKC inhibitor staurosporine, suggesting that
both the PKC and the calcium pathways participate in the CD43-mediated
control of IL-2 gene expression. We also show that CD43 ligation
induced the DNA binding activity of the AP-1, NF B, and NF-AT
transcription factors. These data are consistent with a dual pathway of
activation through the CD43 molecule because AP-1 and NF B activation
result from a transient high peak of calcium and signals coming from
the MAPKs pathway (28-30), whereas NF-AT recruitment depends on a
capacitative calcium entry into the cells (31, 32). Moreover, data
provided here demonstrate that CD43 stimulates the expression of genes
encoding for proteins necessary for T cell effector function and clonal
expansion, such as CD69 as a result of activation of AP-1 and NF B
through the PKC pathway, and CD40-L because of NF-AT recruitment by the
Ca2+ pathway (33-35). Data presented in this study
considerably broaden the role of the CD43 molecule in the control of
gene expression and cell function.
 |
EXPERIMENTAL PROCEDURES |
Reagents--
Two monoclonal antibodies (both IgG1) that
recognize different epitopes of the CD43 molecule were used: L10, which
is specific for an epitope of the protein core (36), and MEM-59, which
recognizes a neuraminidase-sensitive epitope (37). The 3D6 mAb was used as an isotype control for L10 (38). The anti-CD3 mAb OKT3 (IgG2) was
originally obtained from the American Type Culture Collection. mAbs
were used either as ascites or purified. Rabbit anti-mouse IgG was
generated in our laboratory. Polyclonal rabbit antibodies specific for
human p65, c-Fos, c-Jun, NF-ATc, and NF-ATp were from Santa Cruz
Biotechnologies (Santa Cruz, CA). Anti-CD69 mAb (TP1/55) was a kind
gift of Dr. Francisco Sanchez-Madrid (Hospital de la Princesa, Madrid,
Spain), and anti-CD40-L mAb (5C9) was from the American Type Culture
Collection. Ficoll-Hypaque, phorbol myristate acetate (PMA), ionomycin,
cyclosporin A, a calcineurin inhibitor (39), and staurosporine, a PKC
inhibitor (40), were from Sigma. Poly d(I-C) and dNTPs were from
Roche Molecular Biochemicals, T4 polynucleotide kinase was from Promega
(Madison, WI), murine mammary tumor virus reverse transcriptase
and RNase inhibitor were from Life Technologies, Inc., Tfl DNA
polymerase was from Epicenter Technologies (Madison, WI), and
[ -32P]ATP was from NEN Life Science Products.
Cell Culture--
Jurkat cells were cultured in RPMI 1640 (Hyclone, Logan, UT) supplemented with 5% fetal calf serum (Hyclone),
5% bovine iron-supplemented calf serum (Hyclone), 2 mM
L-glutamine (Sigma), 50 units/ml penicillin, 50 µg/ml
streptomycin and, 50 mM -mercaptoethanol. Peripheral blood T cells were isolated from healthy adult donors by Ficoll-Hypaque gradient centrifugation. The mononuclear cells buffy coat was resuspended in supplemented RPMI before plating the cells overnight onto 100-mm Petri dishes (8 × 107 cells/plate) at
37 °C in 5% CO2. Nonadherent cells were loaded on a
nylon column pre-equilibrated with supplemented RPMI. The resultant
purified cells were predominantly TcR+ (>85%
OKT3+) and CD43+ (>95% L10+), as
determined by FACS staining. Prior to experimentation, T cells were
arrested for an additional 24 h in RPMI supplemented with 2%
fetal calf serum. Subsequent manipulations were done in this medium.
T Cell Activation--
Purified T cells or Jurkat cells (1 × 107 cells/ml) were incubated in 24-well plates at
37 °C and 5% CO2 with the following antibodies, alone
or in combination: L10, 1:500 dilution of ascites or 1 µg/ml of
purified IgG; MEM-59, 1 µg/ml; OKT3, 1 µg/ml (optimal, OKT3o) or 10 ng/ml (suboptimal, OKT3s); equivalent amounts of the isotype control
mAb, 3D6 were used for L10 or MEM-59. Additional cross-linking was
achieved by adding rabbit anti-mouse IgG (1 µg/ml) to the wells. As
positive controls, cells were activated with ionomycin (Iono; 1 µg/ml), phorbol myristate acetate (PMA; 50 ng/ml), or a combination
of both. When indicated, cyclosporin A (CsA; 500 ng/ml), staurosporine
(50 nM), or anisomycin (10 mM) were added to
the cultures 15 min prior to activation. 6 h after the onset of
the experiment, cells were collected by centrifugation, washed, and
frozen, when used for IL-2 mRNA determination. Nuclear extracts
were obtained immediately after cell harvest.
Reverse Transcription-PCR--
Total RNA was obtained using
TRIzol (Life Technologies, Inc.) following the
manufacturer's instructions. cDNA was synthesized from 1 µg of
total RNA by standard reverse transcription conditions, using oligo(dT)
as primer in a final volume of 25 µl. IL-2 mRNAs were amplified
from 3 µl of cDNA, using the following oligonucleotides as
primers: 3' (5'-CGT TGA TAT TGC TGA TTA AGT CCC TC-3') and 5' (5'-CAT
TGC ACT AAG TCT TGC ACT TGT CA-3'). PCR was accomplished by one
denaturing cycle of 4 min at 94 °C followed by 30 cycles of
amplification (1 min at 91 °C, 1 min at 60 °C, and 1 min at 72 °C) and one final extension cycle of 15 min at 72 °C to
generate a product of 305 base pairs. As internal control, we evaluated the expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in parallel PCR reactions, using 2 µl of the
same cDNAs with the following oligonucleotides: 3' (5'-TCC ACC ACC
CTG TTG CTG TA-3') and 5' (5'-ACC ACA GTC CAT GCC ATC AC-3'). PCR
conditions for GAPDH were: one denaturing cycle of 5 min at 95 °C,
30 cycles of amplification (1 min at 94 °C, 1 min at 55 °C, and 1 min at 72 °C), and one final extension cycle of 15 min at 72 °C,
resulting in a product of 452 base pairs. Amplified fragments from both
reactions were resolved simultaneously in 4% agarose gels and
visualized with ethidium bromide.
Nuclear Extract Preparation--
Activated cells were washed
with phosphate-buffered saline before obtaining nuclear extracts,
basically as described (41) with the following modifications. Cells
were lysed by incubating them for 5 min at 4 °C in a detergent-free,
hypotonic buffer (10 mM Tris, pH 7.6, 10 mM
NaCl, 1.5 mM MgCl2, 0.5 mM EDTA, 1 mM dithiothreitol, 1 µg/ml leupeptin, and 0.5 mM phenylmethylsulfonyl fluoride). Intact nuclei were
washed with this lysis buffer, and nuclear extracts were obtained by
incubating the nuclei in extraction buffer (20 mM Tris, pH
8.0, 450 mM KCl, 0.5 mM EDTA, 1 mM
dithiothreitol, 1 µg/ml leupeptin, 5 mM spermidine, and
25% glycerol) for 45 min under constant mild agitation at 4 °C. DNA
pellets were eliminated by centrifugation for 15 min at 13,000 × g; protein content of the extracts was determined by
Bradford assay (42).
Electrophoretic Mobility Shift Assays--
Experiments were
conducted basically as described (43), using the following double
stranded oligonucleotides: AP-1, 5'-CGC TTG ATG ACT CAG CCG GAA-3';
NF-AT, 5'-AAA GAA AGG AGG AAA AAC TGT TTC ATA CAG-3'; NF B, 5'-AGT
TGA GGG GAC TTT CCC AGG C-3'; and MCAAT (nonspecific competitor),
5'-CTC CTA TTG GCT TGA-3'.
Briefly, oligonucleotides were end-labeled with T4 polynucleotide
kinase using 30 µCi of -32P-labeled ATP/100 ng of
oligonucleotide. Protein extracts (2.5 µg) from activated T cells
(for 4 h, unless otherwise indicated) were incubated for 20 min at
room temperature with the labeled oligonucleotide (1 × 105 cpm) in band shift buffer (25 mM Hepes, pH
7.9, 40 mM KCl, 3 mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, and 10%
glycerol) containing 1 µg of poly(dI-dC) as a nonspecific competitor.
DNA-protein complexes were resolved on nondenaturing 6% polyacrylamide
gels and visualized by autoradiography.
For competition experiments, 50-fold molar excess of the cold
oligonucleotides was added 5 min before adding the labeled probe, following which the assays were performed as above. For immune band
shift assays, DNA-protein complexes were allowed to form prior to the
addition of 0.1 µg of anti-p65 antibody or 1 µg of anti-c-Jun,
anti-Fos, anti-NF-ATc, or anti-NF-ATp antibodies. Samples were
incubated with the antibody for 5 h at 4 °C prior to resolving
the DNA-protein complexes on 5% polyacrylamide gels. Equivalent
amounts of an irrelevant antibody were used as control.
FACS Staining--
T cells were activated by incubating them
with the indicated amount of PMA in the presence or absence of
anti-CD43 L10 mAb at 37 °C for 18 h. Cells were then collected
and stained for FACS analysis. Briefly, cells (1 × 106) resuspended in 50 µl of phosphate-buffered saline
containing 2% fetal calf serum and 1% sodium azide (FACS solution)
were incubated with anti-CD43 (L10), anti-CD3 (OKT3), biotinylated
anti-CD40-L, or anti-CD69 mAbs for 30 min at 4 °C. Cells were then
washed by centrifugation at 300 × g with FACS solution
and incubated with second step reagent fluorescein isothiocyanate for
30 min at 4 °C and washed as above, following which cells were
resuspended in FACS solution and fixed with 1% paraformaldehyde (final
concentration). Cells were analyzed with a FACSort with the CELLQUEST
program (Becton and Dickinson, San José, CA).
 |
RESULTS |
CD43-dependent IL-2 Gene Expression Involves the PKC
and the Ca2+ Signaling Pathways--
Given the importance
of IL-2 in the proliferative and late stages of T cell activation and
the fact that simultaneous signaling from CD43 and the TcR had been
previously reported to result in IL-2 production (21, 27), we
investigated the molecular mechanisms involved in the
CD43-dependent IL-2 mRNA induction. As shown in Fig.
1, cross-linking CD43 on the surface of
normal human peripheral blood T lymphocytes with two different mAbs,
without co-ligating the TcR, was sufficient to generate signals that
lead to IL-2 mRNA induction (lanes 1 and 4).
When cells were incubated with both anti-CD43 mAbs simultaneously, the
amount of IL-2 mRNA increased approximately 7-fold over control
cells (compare lanes 7, 10, and 11),
although to a lesser extent than when cells were treated with PMA and
ionomycin (lane 14). Independent of the anti-CD43 mAb that
was used to stimulate the cells, signals resulting in the induction of
IL-2 mRNA were blocked by CsA (lanes 3, 6,
and 9) and partially blocked by staurosporine (lanes
2, 5, and 8). Cells treated only with CsA or
staurosporine but no antibody (lanes 12 and 13),
control antibody-treated (lane 11), and untreated cells
(lane 10) had equivalent levels of IL-2 mRNA. The graph shown in the lower panel of Fig. 1 represents the
percentages of change in the IL-2 cDNA/GAPDH cDNA signal. These
data suggest that CD43-mediated signals can induce IL-2 gene
expression, recruiting the PKC and the Ca2+ pathways.

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 1.
IL-2 mRNA expression induced by CD43
cross-linking is partially inhibited by cyclosporin A and
staurosporine. Human peripheral blood T cells were cultured for
6 h in the presence of 1 µg of two different anti-CD43 mAbs, L10
and MEM-59, alone or in combination. CsA or staurosporine
(STAU) were added where indicated 15 min before the mAbs. As
positive control, cells were treated with PMA and Iono. Specific IL-2
mRNA was detected by reverse transcription-PCR. As internal
control, the expression of the housekeeping gene GAPDH was monitored.
Ethidium bromide-stained gels of PCR products (upper panel)
were scanned using computer-assisted densitometry
(Fluor-S-Multi-imager, Bio-Rad) and the data (IL-2 cDNA/GAPDH
cDNA signal) were plotted as the percentages of change (lower
panel). Data shown are representative of four independent
experiments.
|
|
CD43 Induces Binding of AP-1 Transcription Factor to DNA--
To
investigate the pathway leading to CD43-mediated regulation of gene
expression, we looked for the induction of transcription factors
following CD43 ligation, particularly for factors that bind to the IL-2
gene promoter such as AP-1, NF-AT, and NF B (44). Cross-linking CD43
on the surface of Jurkat cells with either anti-CD43 mAb, L10, and/or
MEM-59 promoted the formation of an AP-1 complex over levels of control
cells (Fig. 2, lanes 2,
3, 12, and 13); co-stimulation with
both mAbs did not result in higher levels of AP-1 binding than those
observed when cells were stimulated with MEM-59 alone (lanes
2-4). At this time point, CD43 ligation resulted in higher levels
of AP-1 than ligation with optimal amounts of OKT3 (OKT3o) or
stimulation with PMA (lanes 8 and 9), probably reflecting a difference in kinetics. As expected, ionomycin did not
have any effect on the DNA binding capacity of AP-1 (lanes 10 and 11), because the AP-1 family of transcription
factors is activated by the MAPK pathway and not by the sustained
calcium plateau characteristic of ionomycin.

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 2.
CD43 cross-linking induces AP-1 binding
activity independently of TcR signaling. Electrophoretic mobility
shift assays (EMSAs) were performed with 2.5 µg of nuclear proteins
from Jurkat cells stimulated with L10 and/or MEM-59 (1 µg/ml) and/or
OKT3 at optimal (OKT3o, 1 µg/ml) or suboptimal (OKT3s, 10 ng/ml)
amounts. Extracts treated with PMA, Iono, or both were included as
positive controls. A 32P-end-labeled probe containing the
AP-1 site was used. The arrow indicates the specific
DNA-protein complex. A representative of three independent experiments
is shown.
|
|
To determine the kinetics of the CD43-dependent AP-1
binding activity, human peripheral blood T lymphocytes were activated for different periods of time. Following CD43 cross-linking, AP-1 binding to DNA could be detected as early as 30 min and was maintained for at least 4 h (Fig.
3A, lanes 1,
4, 7, and 10), whereas when cells were
stimulated with PMA and ionomycin, the response was slower, as
reflected by the fact that AP-1 induction could be observed only 1 h after the onset of the experiment (lanes 2, 5,
8, and 11). When cells were treated with control
mAb (3D6), AP-1 binding activity remained constant all through the
experiment (lanes 3, 6, 9, and
12).

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 3.
AP-1-DNA complexes induced by CD43 ligation
contain c-Jun. A, CD43 induces AP-1 binding activity in
a time-dependent manner. Normal human peripheral T
lymphocytes were incubated for the indicated times with mAb L10, PMA
and Iono, or mAb 3D6, as described. Nuclear extracts were prepared and
subjected to EMSAs with the AP-1 probe. The arrow indicates
the position of the induced complex. Results were confirmed in three
independent experiments. B, AP-1 complexes induced by
CD43-mediated signals are specific. Human T lymphocytes were
CD43-stimulated for 4 h, and nuclear extracts were used for
competition experiments with 50-fold excess of the indicated cold
oligonucleotides. The arrow indicates the position of the
complex. C, AP-1 complexes induced by CD43 ligation contain
c-Jun. Nuclear extracts from anti-CD43 mAb L10-treated normal human T
lymphocytes were incubated with the AP-1 probe before adding anti-c-Jun
or an irrelevant antibody (Control). The lower
arrow indicates the position of the induced complex, and the
upper arrow indicates that of the supershifted
complex.
|
|
Specificity of the DNA-AP-1 complexes formed following CD43 ligation
was demonstrated by competition experiments (Fig. 3B), where
AP-1 binding to the labeled probe was competed with a 50-fold molar
excess of cold AP-1 oligonucleotide (lanes 1 and
2), whereas similar amounts of a nonspecific
oligonucleotide, M-CAAT, had no effect (lane 3). Because
c-Jun is one of the most common members of AP-1 (45), we investigated
whether it was present in the DNA-AP-1 complexes generated through
CD43. As shown in Fig. 3C, when nucleoprotein complexes were
incubated with anti-Jun antibodies, a partial supershift could be
observed (lane 2), thus indicating the presence of c-Jun.
Other members of the Jun family, however, might also be present,
because the induced complexes did not disappear completely following
supercomplex formation. Various members of the AP-1 family of proteins
(c-Fos, Fos B, c-Jun, JunB, and Fra1) have been implicated in gene
regulation upon T cell activation (46, 47). Altogether these data
suggest that AP-1 participates in the CD43-specific signaling pathway
leading to gene expression.
We had previously shown that simultaneous stimulation through the CD43
molecule and the TcR-CD3 complex resulted in enhanced IL-2 production
(21). Here, we activated normal human peripheral blood T cells with
saturating amounts of the anti-CD43 mAbs L10 or MEM-59 alone or in
combination with suboptimal concentrations of OKT3 (OKT3s) for 4 h
and evaluated the AP-1 binding activity. As shown in Fig. 2,
integrating signals generated through the TcR with OKT3s and through
CD43 with L10 or MEM-59 did not result in enhanced DNA binding activity
of AP-1 as compared with cells activated either through the TcR alone
or the CD43 molecule alone (lanes 2, 3,
5, 6, and 7). In fact, at this
time point (4 h), an inhibitory effect was observed when OKT3s was used
in combination with the anti-CD43 mAbs, suggesting an eventual
cross-talk between the TcR and the CD43 signaling pathways.
CD43 Cross-linking Induced Two Complexes Recognizing a Composite
NF-AT/AP-1 Site--
We investigated next whether CD43 signaling would
lead to NF-AT binding to DNA when Jurkat cells were activated for
4 h with L10, MEM-59, or both mAbs, with or without suboptimal
amounts of OKT3 or with PMA and/or ionomycin. When cells were treated with PMA, a fast migrating complex was observed (Fig.
4, lane 9, complex
a) that corresponds to AP-1 binding to the NF-AT site (48, 49).
Ionomycin treatment induced the formation of a second DNA-protein
complex (complex b, lane 10) that corresponds to
NF-AT binding to its cognate site (48, 50). In addition to complexes a and b, treatment with PMA and ionomycin
resulted in the formation of a third complex (complex c,
lane 11) that contains AP-1 and NF-AT bound simultaneously
to the composite NF-AT/AP-1 site (48, 51). Ligation of CD43 with either
anti-CD43 mAb resulted in the formation of complex a
(lanes 2 and 3). Simultaneous cross-linking of
CD43 with MEM-59 and L10 induced the formation of complexes a and b, suggesting an additive effect of signals
generated through each epitope (lane 4). Stimulation of the
cells with OKT3o promoted also the formation of complexes a
and b (lane 8), whereas OKT3s induced only AP-1
binding activity (complex a, lane 5). Co-ligation of CD43 through the MEM-59 mAb with OKT3s resulted in enhanced AP-1 DNA
binding activity (complex a) as well as in the translocation of NF-AT (complex b) to the nucleus (lane 7);
complex b contained NF-AT because immune band shift
experiments showed that complex b was supershifted in the
presence of anti-NF-ATc antibody (Fig. 5C) and because this complex
was inhibited by cyclosporin A (Fig. 5D). None of the
stimuli was capable of inducing the supercomplex formation that
resulted from PMA and ionomycin simultaneous addition (Fig. 4,
lane 11). When the experiment was done with unstimulated cells or cells treated with the secondary antibody only, none of these
complexes were induced (Fig. 4, lanes 12 and
13).

View larger version (101K):
[in this window]
[in a new window]
|
Fig. 4.
CD43 cross-linking induces binding activity
to the distal NF-AT site of the IL-2 promoter. Jurkat cells were
treated with 1 µg/ml of L10, MEM-59, and/or OKT3 at optimal (1 µg/ml, OKT3o) or suboptimal (10 ng/ml, OKT3s) amounts for 4 h,
following which nuclear extracts were obtained and used for EMSA, using
a 32P -labeled probe containing the distal NF-AT site of
the IL-2 promoter. Extracts from cells treated with PMA, ionomycin, or
both were included as positive controls; negative controls were
provided by extracts from cells treated only with second antibody
(rabbit anti-mouse IgG, RaMIG) or from unstimulated cells.
The different inducible complexes were designated as a
(AP-1), b (NF-AT), and c (AP-1/NF-AT). Data shown
are representative of three independent experiments.
|
|

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 5.
NF-AT binding activity induced by CD43
involves both AP-1 and NF-AT proteins. A, CD43-induced
NF-AT complexes are specific. Nuclear extracts (5 µg) from Jurkat
cells co-stimulated with 1 µg/ml of each L10 and MEM-59 for 4 h
were used for competition experiments in the presence of either 10- or
50-fold excess of the indicated cold oligonucleotides The
arrows indicate the positions of induced complexes.
B, within the NF-AT/AP-1 composite site, AP-1 complexes
comprise c-Jun and c-Fos. Nuclear exctracts from MEM-59 stimulated
Jurkat cells were incubated with the NF-AT probe as described before,
following which DNA-protein complexes were incubated with anti-Jun,
anti-Fos, or control antibody (anti-CDC42) and separated as described
under "Experimental Procedures." C, complexes induced by
CD43 contain NF-ATc. Nuclear extracts from ionomycin-treated Jurkat
cells were incubated with the probe as described, prior to the addition
of anti-NF-ATc, anti-NF-Atp, or control antibody (anti-CDC42). The
lower arrow indicates the position of complex b,
and the upper arrow indicates the position of the
supershifted complex (bs). D,
CD43-induced NF-AT complexes formation is inhibited by CsA. Human
peripheral blood T lymphocytes were treated with L10 or MEM-59 mAbs, in
the presence or absence of CsA for 4 h. EMSA analysis was
performed with 2.5 µg of nuclear extracts protein and
32P-labeled NF-AT site containing probe. The
arrows indicate the positions of the induced
complexes.
|
|
To investigate the nature of the two NF-AT recognizing complexes
induced following CD43 cross-linking on Jurkat cells, competition experiments were performed with oligonucleotides containing the composite NF-AT/AP-1-binding site or the AP-1 consensus-binding site.
In Fig. 5A, we show that complex a was partially
competed with both oligonucleotides, confirming that this complex
contained AP-1 (lanes 1-5), whereas addition of an
unrelated oligonucleotide had no effect on complex a
formation (lanes 6 and 7). A 10-fold molar excess
of composite NF-AT oligonucleotide inhibited the formation of complex
b (lanes 1-3), whereas comparable amounts of the
AP-1 oligonucleotides had no effect (lanes 4 and
5), and MCAAT had only a slightly inhibitory effect
(lanes 6 and 7).
To demonstrate that complex a induced by CD43 contained
AP-1, DNA-protein complexes were allowed to react with anti-Fos,
anti-Jun, or a nonspecific antibody (Fig. 5B). Addition of
either anti-Fos or anti-c-Jun resulted in partial inhibition of complex
a formation (lanes 2 and 3), whereas
the nonspecific antibody had no effect (lane 4). The
presence of NF-ATc in complex b was demonstrated by the fact
that incubation of DNA-protein complexes from ionomycin-treated Jurkat
cells with anti-NF-ATc antibody induced a supershift (Fig. 5C, lane 3), whereas anti-NF-ATp antibody had no
effect (lane 2). Moreover, in normal human T lymphocytes,
induction of complex b but not complex a was
inhibited when cells were treated with cyclosporin A prior to
CD43 cross-linking (Fig. 5D, lanes 2 and 4).
Co-ligation of CD43 with the L10 mAb and suboptimal amounts of anti-CD3
OKT3 mAb resulted also in reduction of the AP-1 binding activity
(complex a) to both the composite NF-AT/AP-1 site (Fig. 4,
lanes 2 and 6), and the AP-1 consensus site (Fig.
2, lane 6). On the contrary, co-ligation with the anti-CD43
mAb MEM-59 and suboptimal amounts of anti-CD3 OKT3 mAb resulted in
higher AP-1 binding activity (Fig. 4, lanes 3 and
7). Under these conditions, NF-AT binding (complex
b) was also induced.
Together, these results show that CD43-mediated signals induce AP-1 and
NF-AT DNA binding activity to the distal NF-AT site of the IL-2
promoter, that different anti-CD43 mAb generate slightly different
intracellular signals, and that, depending on the anti-CD43 mAb,
TcR-mediated signals modulate the DNA-binding pattern to the composite
NF-AT/AP-1 site of the IL-2 promoter.
CD43 Signaling Induces NF B--
The NF B family of
transcription factors controls the expression of numerous cytokine
genes involved in T cell function (for review see Ref. 52). We
investigated whether CD43 signaling would induce NF B activity. As
shown in Fig. 6, cross-linking CD43 on
the surface of normal human T cells with the L10 mAb induced NF B
binding activity in a time-dependent manner. NF B
induction could be observed within 1 h, reaching a maximum at
2 h and remaining constant for up to 4 h after stimulation
(lanes 2, 6, 10, and 14).
Interestingly, induction of NF B DNA binding activity following CD43
ligation with equivalent amounts of MEM-59 mAb was detected only 4 h after stimulation (lanes 3, 7, 11,
and 15). The kinetics of NF B binding activity induced by
PMA and ionomycin treatment was faster, reaching a maximum as early as
30 min and decreasing slowly thereafter (lanes 4,
8, 12, and 16). In all cases, the NF B activity mediated through the CD43 molecule was weaker than that
observed for PMA- and ionomycin-treated cells. Incubation with
control mAb (3D6) did not result in induction of NF B binding activity (lanes 5, 9, 13, and
17).

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 6.
CD43 ligation induced specific
NF B binding activity in a
time-dependent manner. Human T lymphocytes were
incubated with 1 µg/ml of L10, MEM-59, or 3D6 mAbs or with PMA and
ionomycin for 0.5, 1, 2, or 4 h. Nuclear extracts were used for
EMSA with a 32P-labeled probe containing the consensus
NF B site. The arrow indicates the induced DNA-protein
complex. A representative experiment out of three is shown.
|
|
Specificity of the NF B-DNA complexes resulting of CD43 ligation was
demonstrated by competition assays where the addition of 50-fold molar
excess of cold NF B abolished DNA binding (Fig. 7A, lane 3). No
competition was observed when the same amount of the unspecific
oligonucleotide MCAAT was added (lane 2). Additional proof
that NF B was present in those complexes came from immune band shift
experiments. When the NF B-DNA complexes induced after CD43
engagement (Fig. 7B) were treated with anti-p65 antibody, a
supershift was observed correlating with the disappearance of the
specific NF B complex (lane 3), demonstrating that the
CD43-mediated NF B binding activity involves p65. Addition of a
control antibody had no effect on the electrophoretic mobility of the
DNA-protein complexes (lane 2). Altogether, these data show
clearly that NF B binding activity is induced by
CD43-dependent signals.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 7.
The CD43-dependent
NF B complex contains p65 (Rel A).
A, CD43-induced NF B complexes are specific. Competition
assays with 50-fold excess of cold NF B or MCAAT oligonucleotides
were done with nuclear extracts from human T lymphocytes isolated from
peripheral blood, treated for 4 h with 1 µg/ml L10 mAb. The
arrow indicates the position of the induced complex.
B, CD43-induced NF B complexes contain p65. Nuclear
extracts from human T lymphocytes, stimulated for 2 h in the
presence of mAb L10, were used for supershift assays with an anti-p65
antibody. The lower arrow indicates the induced complex, and
the upper arrow indicates the p65 supershifted complex
(NF Bs).
|
|
CD43 Ligation Induces the Expression of CD69 and CD40-L in T
Lymphocytes--
The induction of AP-1, NF-AT, and NF B by
CD43-mediated signals implicated a potential role for this molecule in
the expression of genes with recognition sites for these transcription
factors in their promoters. To test this possibility, we investigated the effect of CD43 cross-linking on CD69 expression in human peripheral blood T cells. CD69 is an early marker of T cell activation whose expression is mediated by NF B activation in response to tumor necrosis factor (33) or by the proximal AP-1 site of the CD69 promoter region in response to TcR/CD3 cross-linking or PMA treatment (34). As shown in Fig. 8A,
ligation of CD43 with the L10 or MEM 59 mAbs for 18 h resulted in
a modest induction of CD69 expression with 5.3 ± 0.89 and
6.1 ± 2.0% CD69+ cells, respectively, whereas when
incubated with the isotype control (3D6) only 1% of the cells were
CD69+. As expected, TcR- and PMA-mediated activation
resulted in higher percentages of CD69+ cells with 24 ± 2.5 and 72 ± 14.5% CD69+ cells, respectively.
Because CD43 cross-linking resulted only in a weak induction of CD69
expression, we asked whether CD43 signals could enhance PMA-mediated
CD69 expression. To test this possibility, human peripheral T cells
were treated with different amounts of PMA alone or in combination with
the anti-CD43 L10 mAb. As shown in Fig. 8B, although
stimulation with 0.01 ng/ml of PMA did not induce CD69 expression,
co-stimulation with the L10 mAb resulted in the same low levels of CD69
expression 4-5% (Fig. 8A) as observed with the L10 mAb
alone. A higher dose of PMA (0.1 ng/ml) induced CD69 expression in
90 ± 5% of the cells, with a mean fluorescence intensity (MIF)
of 61 ± 10. When cells were treated simultaneously with the L10
mAb and PMA (0.1 ng/ml), 100% of the cells were CD69+ and
the MIF almost doubled (MIF = 115 ± 7), compared with PMA alone. Stimulation with 50 ng/ml of PMA resulted in approximately three
times higher CD69 expression (MIF = 196 ± 12), and
co-stimulation by CD43 cross-linking further increased it (MIF = 258 ± 15). These data indicate that CD43 signaling induces CD69
expression and that CD43-dependent signals cooperate in an
additive fashion with PMA signaling to enhance the expression of CD69,
probably by an AP-1- and NF B-dependent mechanism.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 8.
CD43 ligation enhances the expression of CD69
and CD40-L. A, human peripheral T cells were stained
for CD69 after 18 h stimulation with 1 µg/ml L10 or MEM-59
anti-CD43 mAbs, 1 µg/ml anti-CD3 mAb OKT3, PMA, or isotype control
antibody 3D6. B, human peripheral T cells were stained for
CD69 after 18 h co-stimulation with L10 and different amounts of
PMA. C, to evaluate CD40-L expression, cells were stained
after 8 h the indicated stimuli. Data shown represent the average
of three independent experiments.
|
|
CD40 ligand (CD40-L) is transiently expressed on activated T cells and
interacts with CD40, a constitutively expressed molecule present on
antigen presenting cells. It was recently shown that deletion of a
proximal composite NF-AT site of the CD40-L promoter reduced
transcriptional activity of this gene to background levels, suggesting
that the Ca2+ pathway plays an important role in CD40-L
expression (35).3
Because CD43 signaling involves Ca2+ mobilization and NF-AT
DNA binding activity, we tested whether CD43 signaling induced CD40-L
expression in human peripheral T cells. As shown in Fig. 8C,
CD40-L expression in human peripheral T cells is clearly dependent on
Ca2+ signaling, because 95 ± 8% of the cells were
CD40-L+ after 8 h treatment with ionomycin, whereas
PMA treatment resulted only in 2.7 ± 0.7% of CD40-L+
cells. When CD43 was cross-linked with L10 or MEM 59 mAbs, 12.86 ± 2 and 16.62 ± 1.5%, respectively, of the cells were
CD40-L+. Cells treated with 3D6 (isotype control) showed
basal CD40-L expression (3.6%+0.8). When cells were activated through
the TcR, 45 ± 3% of the cells were CD40-L+. These
results show that CD43 signaling induces the expression of CD40-L, most
probably through Ca2+ mobilization and the induction of
NF-AT binding activity to the proximal NF-AT site of CD40-L. All
together the data provided here show that CD43 signaling can positively
regulate the expression of different genes containing AP-1, NF B, or
NF-AT responsive elements in their regulatory regions.
 |
DISCUSSION |
Reports regarding the role of CD43 involve this co-receptor
molecule in multiple aspects of cell function, yet the molecular basis
of CD43 signaling is only partially understood. The participation of
CD43 in T cell function (13-22) prompted us to search for the CD43
signaling pathway. The ideal way to evaluate the signaling capacity of
a molecule would be to use natural ligands; however, in the case of
CD43, this is particularly difficult because all the ligands that have
been described so far are also ligands of other T cell surface
molecules (10-12). To mimic the interaction with its ligands, CD43 was
cross-linked on the cell surface with two different anti-CD43
monoclonal antibodies, L10 and MEM-59. Independent of the antibody
used, CD43 signals were sufficient to induce IL-2 mRNA, and an
additive effect was observed when both anti-CD43 mAbs were used
simultaneously (Fig. 1). Consistent with previous reports showing that
CD43 ligation resulted in both PKC activity and Ca2+ flux
(23, 25), we found that CD43-mediated IL-2 mRNA induction was
partially inhibited by cyclosporin A and staurosporine, regardless of
whether the cells were activated with either mAb alone or in combination (Fig. 1). This dual pathway of activation was further confirmed by the CD43-dependent induction of CD69 and
CD40-L (Fig. 8), whose expression depend on the MAPKs and the
Ca2+ pathways, respectively (33-35).
Initial steps of T cell activation are orchestrated through the
recruitment of several transcription factors, including NF-AT, AP-1 and
NF B (2, 44, 53). Cross-linking CD43 with either L10 or MEM-59 mAbs
on Jurkat cells resulted in the induction of AP-1 DNA binding activity
(Fig. 2). Complexes between the AP-1 probe and nuclear proteins were
formed as early as 30 min following CD43 ligation and were still
present after 4 h. These complexes were specific and contained
c-Jun as evidenced by the supershift induced in the presence of
anti-c-Jun antibody (Fig. 3) and the inhibition of the AP-1-NF-AT
composite site by anti-Fos or anti-Jun antibodies. The differential
behavior of anti-Jun antibody on the complex formation between c-Jun
and the AP-1 or NF-AT/AP-1- sites could be due to the different
affinity of c-Jun for either site. The fact that not all protein-DNA
complexes supershifted when incubated with the anti-c-Jun antibody
suggests that other members of the Jun family may be recruited in
response to CD43 ligation. In T cells, AP-1 activity is tightly
regulated by the MAPKs pathway at the transcriptional and
posttranslational levels, increasing the amounts and enhancing the
stability and binding activity of AP-1 proteins through phosphorylation
(for review see Ref. 45). The CD43-mediated AP-1 activity reported here may result of signals generated through the MAPK pathway because we
have shown that CD43 signaling leads to ERK2 activation and nuclear
localization and to Fos-SRE-dependent transcription
(26).4
Four different NF-AT proteins expressed in lymphoid cells as well as in
other cell types have been described (54). Upon dephosphorylation by
the calmodulin-dependent phosphatase calcineurin, NF-AT
proteins become activated and translocate to the nucleus. The NF-AT
transcription factors can bind to DNA directly or in combination with
AP-1 family members (for review see Ref. 31). We report here that
CD43-specific signals induced two specific NF-AT DNA-protein complexes
(Fig. 4). One of the complexes, similar to that generated by incubating
the cells with PMA, contained AP-1 proteins and was CsA-resistant.
Interestingly, CD28 and PMA signaling have been shown to result in
activation of the IL-2 promoter by NF-AT proteins in a CsA-resistant
manner. The complex formed under such conditions was also competed by
AP-1 sequences (49). This is particularly relevant considering the fact
that CD43 has been shown to be a substitute for CD28 function in
CD28 / mice (22). Induction of the second CD43-mediated
NF-AT complex, equivalent to that generated by ionomycin, required
simultaneous cross-linking of CD43 with L10 and MEM-59 mAbs on Jurkat
cells. However, in peripheral blood T lymphocytes, signals generated through either mAb were sufficient to induce that nucleoprotein complex, in a CsA-sensitive way.
Transient peaks of intracellular calcium result in AP-1 and NF B
activation (28-30). Data reported here show that the molecular events
following CD43 cross-linking involved AP-1 and NF B induction, correlating with the transient peak of intracellular calcium reported upon CD43 ligation on HPB-ALL or Jurkat cells with L10 or MEM-59, respectively (23, 25). Our results suggest that ligation with either
mAb was not sufficient to induce NF-AT translocation to the nucleus in
Jurkat cells but that the sustained elevated calcium concentrations
required for NF-AT activation (31, 32) were presumably achieved when
Jurkat cells were activated through simultaneous cross-linking of CD43
with L10 and MEM-59, because NF-AT DNA binding activity could be
observed only under those conditions (Fig. 4). In peripheral blood T
cells, however, the sustained Ca2+ fluxes that were
reported following CD43 ligation with MEM-59 (25) correlate well with
the NF-AT activity we report here with either mAb alone (Fig.
5D). The different responses we observed between peripheral
blood normal T lymphocytes and Jurkat cells to CD43 ligation with
different anti-CD43 mAbs could be due to a higher threshold for
specific gene induction in actively dividing cells. Another possible
explanation for the need of the combined effect of L10 and MEM-59 in
Jurkat cells could be that particular epitopes of the CD43 molecule
initiate different signaling events that eventually result in the
additive induction of IL-2 mRNA we observed (Fig. 1).
The NF B family proteins regulate the transcription of a wide range
of genes, some of which play a central role in immunological processes.
When inactive, these proteins reside in the cytoplasm, associated with
specific IkB inhibitors that are degraded upon serine phosphorylation,
allowing translocation of NF B factors to the nucleus. MAPKs and PKC
participate in the regulation of IkB kinases activity (29). We found
that cross-linking CD43 on the surface of peripheral T lymphocytes
resulted in a time-dependent induction of NF B-DNA
complexes containing p65, as determined by supershift formation in the
presence of anti-p65 antibody (Figs. 6 and 7). Similar experiments
performed with an anti-c-Rel antibody indicated that c-Rel was
not present in those complexes (data not shown), consistent with the
fact that the presence of c-Rel in NFkB complexes is a late response
and that p65 recruitment precedes and is required for c-Rel expression.
p65 translocation to the nucleus during inflammatory and immune
responses is well documented (for review, see Refs. 55 and 56). Thus,
our results suggest that CD43 participates actively in immune response
modulation. However, not all CD43-mediated signals result in NF B
recruitment and T cell activation. In a recent report where Jurkat
cells were activated through the CD43-specific mAb J393, cells were
found to undergo apoptosis. The molecular mechanisms underlying this event were associated with NF B down-regulation (57), because this
transcription factor has been linked with an anti-apoptotic function
(58-60). Consistent with this, the CD43-dependent NF B activity we report in this study did not correlate with
apoptosis.5 The fact that
ligation of CD43 with two different monoclonal antibodies resulted in
opposite effects on NF B activity (this report and Ref. 57) supports
the idea that different anti-CD43 monoclonal antibodies generate
different signals and biological responses.
Altogether, data shown here, in combination with other reports where
CD43 has been described as a signaling molecule (13-22), suggest that
by regulating the activation of several transcription factors, CD43 has
an important participation in cell signal and function. To further test
that CD43-mediated induction of AP-1, NF B, and NF-AT transcription
factors could result in the induction of T cell activation genes, we
tested the effect of CD43 ligation upon the induction of CD69, whose
transcription depends upon AP-1 or NF B activities (33, 34), and that
of CD40-L, which is induced mainly by NF-AT ((Fig. 8). CD43 ligation
slightly but significantly increased the amount of CD69 positive cells
and cooperated with PMA signals by further increasing both the amount of cells that were CD69+ and the density of CD69
molecules/cell. CD43 signals also resulted in an increased CD40-L
expression, presumably through the activation of NF-AT transcription
factors. The low percentage of CD40-L+ and
CD69+ cells resulting of CD43 ligation suggested that a
particular subset of cells was able to express these molecules.
However, these cells did not correspond exclusively to a memory cell
phenotype nor to the  lineage (data not shown).
Considering that CD43 expression and signals might target specific
subsets of memory and effector T cells (61), further experiments are
needed to characterize these cells. In a recent report it was shown
that CD43 ligation on the surface of dendritic cells induces the
expression of IL-1 , tumor necrosis factor , IL-6, IL-12, and
IL-10, leading to macrophage activation (62). The promoters of IL-1
and tumor necrosis factor are regulated by AP-1 (63, 64),
functional roles for AP-1, CREB, NF B, and NF-IL-6 have been
described for the IL-6 promoter (65), and NF B-mediated induction of
IL-12 has been reported (66), further suggesting the participation of
these transcription factors in the CD43-dependent gene expression.
T cell activation is the result of a series of intracellular events
initiated through the specific interaction of multiple cell surface
molecules with their counter-receptors. We have shown here that the
AP-1 binding activity, either to the consensus site or to the AP-1 site
of the NF-AT composite sequence upon ligating CD43 alone on the cell
surface with the L10 mAb was diminished by minimal concomitant TcR
signaling (Fig. 3). This down-modulation correlated with a reduction in
IL-2 mRNA when cells were co-stimulated under the same experimental
conditions for the same length of time (data not shown). On the other
hand, co-stimulation with the anti-CD43 mAb MEM-59 rather than L10
(Fig. 5), resulted in inhibition of AP-1 binding activity to the
consensus site but increased binding activity to the AP-1 site of the
NF-AT composite sequence. Furthermore, co-ligation with this mAb also
resulted in NF-AT translocation to the nucleus, probably because of a
longer calcium flux and to the switch from a MAPK-dependent
to a Ca2+-dependent response (28). However,
when cells where co-stimulated with either L10 or MEM-59 and OKT3 for
24 h, IL-2 mRNA production and IL-2 secretion to the
medium were enhanced.6
Thus, cross-linking CD43 with different mAbs results in different signals that in turn will be regulated differentially by concomitant TcR ligation. This cross-talk modulates the AP-1 binding activity to
different sequences, suggesting that different sets of genes could be
turned on or off, depending of the epitope of the CD43 molecule that is
being recognized by a given ligand and whether the TcR is being
activated or not. Additional examples of cross-talk between CD43 and
other cell surface molecules have been described. Enhanced
LFA-1-dependent homotypic aggregation was shown following up-regulation of CD43 expression by retinoic acids (67), correlating with previous reports where, upon activation with anti-CD43 mAbs, integrin-mediated cell adhesion and movement were up-regulated (68,
69). A mutual activation of CD43 and CD2 adhesive function has also
been described (12), further documenting the cross-talk between
co-receptors.
The CD43-dependent induction of IL-2 mRNA, CD69, and
CD40-L expression and activation of DNA binding activity of AP-1,
NF-AT, and NF B implicate an important role for this molecule in the regulation of gene expression. Further work on CD43 signaling and
control of gene expression in different scenarios will forward understanding of the multiple regulatory effects of CD43.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Leonor Pérez-Martinez and
Dr. Roberto González-Amaro for helpful discussions and
suggestions, Dr. Eduardo Huerta for leukocyte concentrates and Erika
Melchy for technical help.
 |
FOOTNOTES |
*
This work was supported by Grants IN210496 and IN217498 from
Dirección General de Apoyo al Personal
Académico/Universidad Nacional Autónoma de México and
Grants 5230-N and 25307-M from the Consejo Nacional de Ciencia y
Tecnologia, Mexico.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed. Tel.: 52-73-29-16-63;
E-mail: yvonne@ibt.unam.mx.
Published, JBC Papers in Press, July 24, 2000, DOI 10.1074/jbc.M005231200
2
Y. Rosenstein, unpublished data.
3
H. Lindgren, personal communication.
4
G. Pedraza-Alva, unpublished data.
5
M. A. Mendes-Teapila, unpublished data.
6
Y. Rosenstein, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
TcR, T cell
receptor;
mAb, monoclonal antibody;
MAPK, mitogen-activated protein
kinase;
IL, interleukin;
AP-1, activator protein-1;
NF B, nuclear
factor B;
NF-AT, nuclear factor of activated T cells;
PMA, phorbol
myristate acetate;
Iono, ionomycin;
CsA, cyclosporin A;
PKC, protein kinase C;
MIF, mean fluorescence intensity;
IL, interleukin;
FACS, fluorescence-activated cell sorter;
PCR, polymerase chain
reaction;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
CD40-L, CD40
ligand;
EMSA, electrophoretic mobility shift assay.
 |
REFERENCES |
| 1.
|
Lenschow, D. J.,
Walunas, T. L.,
and Bluestone, J. A.
(1996)
Annu. Rev. Immunol.
14,
233-258
|
| 2.
|
Alberola-Ila, J.,
Takaki, S.,
Kerner, J. D.,
and Perlmutter, R.
(1997)
Annu. Rev. Immunol.
15,
125-154
|
| 3.
|
Cyster, J. G.,
Shotton, D. M.,
and Williams, A. F.
(1991)
EMBO J.
10,
893-902
|
| 4.
|
Shelley, C. S.,
Remold-O'Donnell, E.,
Davis, A. E., III,
Bruns, G. A. B.,
Rosen, F. S.,
Carroll, M. C.,
and Whitehead, A. S.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
2819-2823
|
| 5.
|
Pallant, A.,
Eskenazi, A.,
Mattei, M. G.,
Fournier, K. R. E.,
Carlsson, R. S.,
Fukuda, M.,
and Frelinger, G. J.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
1328-1332
|
| 6.
|
Jones, A. T.,
Federsppiel, B.,
Ellies, L. G.,
Williams, M. J.,
Burgener, R.,
Duronio, V.,
Smith, A. A.,
Takei, F.,
and Ziltener, H. J.
(1994)
J. Immunol.
153,
3426-3439
|
| 7.
|
Ellies, L. G.,
Tao, W.,
Fellinger, W.,
Teh, H. S.,
and Ziltener, H. J.
(1996)
Blood
88,
1725-1732
|
| 8.
|
Giordanengo, V.,
Limouse, M.,
DesroysDu Roure, L.,
Cottalorda, J.,
Doglio, A.,
Passeron, A.,
Fuzibet, J. G.,
and Lefebre, J. C.
(1995)
Blood
86,
2302-2311
|
| 9.
|
Remold-O'Donnell, E.,
Davis III, A. E.,
Kenney, D.,
Ramakrishnan Bhask, K.,
and Rosen, F. S.
(1986)
J. Biol. Chem.
261,
7526-7530
|
| 10.
|
Rosenstein, Y.,
Park, J. K.,
Hahn, W. C.,
Rosen, F. S.,
Bierer, B. E.,
and Burakoff, S. J.
(1991)
Nature
354,
233-235
|
| 11.
|
Perillo, N. L.,
Pace, K. E.,
Seihamer, J. J.,
and Baum, L. G.
(1995)
Nature
378,
736-739
|
| 12.
|
Stöckl, J.,
Majdic, O.,
Kohl, P.,
Pickl, W. F.,
Menzel, J. E.,
and Knapp, W.
(1996)
J. Exp. Med.
184,
1769-1779
|
| 13.
|
Manjunath, N.,
Johnson, R.,
Stauton, D. E.,
Pasqualini, R.,
and Ardman, B.
(1993)
J. Immunol.
151,
1528-1534
|
| 14.
|
Manjunath, N.,
Correa, M.,
Ardman, M.,
and Ardman, B.
(1995)
Nature
377,
535-538
|
| 15.
|
Stockton, B. M.,
Cheng, G.,
Manjunath, N.,
Ardman, B.,
and von Andian, U. H.
(1988)
Immunity
8,
373-381
|
| 16.
|
Cyster, J. G.,
and Williams, A. F.
(1992)
Eur. J. Immunol.
22,
2565-2572
|
| 17.
|
De Smet, W.,
Walter, H.,
and Van Hove, L.
(1993)
Immunology
76,
46-54
|
| 18.
|
Chen, S.,
Alon, R.,
Fuhlbrigge, R. C.,
and Springer, T. A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3172-3177
|
| 19.
|
Rosenstein, Y.,
Santana, M. A.,
and Pedraza-Alva, G.
(1999)
Immunol. Res.
20,
89-99
|
| 20.
|
Osterberg, J. R.,
Barth, R. K.,
and Frelinger, J. G.
(1998)
Immunol. Today
19,
546-550
|
| 21.
|
Park, J. K.,
Rosenstein, Y. J.,
Remold-O'Donnell, E.,
Bierer, B. E.,
Rosen, F. S.,
and Burakoff, S. J.
(1991)
Nature
350,
706-709
|
| 22.
|
Sperling, A. I.,
Green, J. M.,
Mosley, R. L.,
Smith, P. L.,
DiPaolo, R. J.,
Klein, J. R.,
Bluestone, J. A.,
and Thompson, C. B.
(1995)
J. Exp. Med.
82,
139-146
|
| 23.
|
Wong, R. C. K.,
Remold-O'Donnell, E.,
Vercelli, D.,
Sancho, J.,
Terhorst, C.,
Rosen, F.,
Geha, R.,
and Chatila, T.
(1990)
J. Immunol.
144,
1455-1460
|
| 24.
|
Pedraza-Alva, G.,
Mérida, L. B.,
Burakoff, S. J.,
and Rosenstein, Y.
(1996)
J. Biol. Chem.
271,
27564-27568
|
| 25.
|
Alvarado, M.,
Klassen, C.,
Cerny, J.,
Horejsi, V.,
and Schmidt, R. E.
(1995)
Eur. J. Immunol.
25,
1051-1055
|
| 26.
|
Pedraza-Alva, G.,
Mérida, L.,
Burakoff, S. J.,
and Rosenstein, Y.
(1998)
J. Biol. Chem.
273,
14 | |